<DOC>
	<DOCNO>NCT00696332</DOCNO>
	<brief_summary>The purpose study ass efficacy , tolerability safety oral administration talampanel compare placebo subject ALS .</brief_summary>
	<brief_title>Talampanel Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Subjects sporadic familial ALS classify definite , probable , laboratorysupported probable ALS accord revise El Escorial criterion . 1 . Diagnosis definite probable ALS accordance ElEscorial criterion . 2 . Subject experience his/her first ALS symptom within 3 year prior screen visit . 3 . Slow VC test equal great 70 % predict value . 4 . The sum 3 respiratory item ALSFRSR must total least 10 point . 5 . Subjects take riluzole must stable dose least 8 week prior screen visit . 6 . Ages 1880 ( inclusive ) 1 . The use invasive noninvasive ventilation . 2 . Subject undergone gastrostomy . 3 . Subject clinically significant unstable medical condition . 4 . Subject participate investigational drug trial use investigational drug ( within 12 week prior screen thereafter ) . 5 . Females pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>ALS</keyword>
</DOC>